Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VC005 in Rheumatoid Arthritis
NCT05874622Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VC-005 in rheumatoid arthritis (RA) (6 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Peak Time in Plasma at Day 28 and Peak Plasma Concentration at Day 28. Started Jun 2023; status: completed.
02
Drugs
VC-005
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05874622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874622.